Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Verastem Inc (VSTM)

Verastem Inc (VSTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 445,396
  • Shares Outstanding, K 66,776
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -130,640 K
  • EBIT $ -160 M
  • EBITDA $ -160 M
  • 60-Month Beta 0.41
  • Price/Sales 30.18
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 462.97% (+153.93%)
  • Historical Volatility 73.43%
  • IV Percentile 98%
  • IV Rank 80.86%
  • IV High 556.08% on 01/23/26
  • IV Low 69.58% on 03/12/25
  • Expected Move (DTE 10) 1.22 (18.28%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 58
  • Volume Avg (30-Day) 256
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 9,470
  • Open Int (30-Day) 9,380
  • Expected Range 5.43 to 7.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.49
  • Number of Estimates 1
  • High Estimate -0.49
  • Low Estimate -0.49
  • Prior Year -1.33
  • Growth Rate Est. (year over year) +63.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.01 +10.65%
on 02/02/26
7.74 -14.08%
on 01/12/26
-1.14 (-14.63%)
since 01/09/26
3-Month
6.01 +10.65%
on 02/02/26
10.82 -38.55%
on 11/26/25
-1.42 (-17.60%)
since 11/07/25
52-Week
4.01 +65.84%
on 06/30/25
11.24 -40.86%
on 09/05/25
+0.86 (+14.85%)
since 02/07/25

Most Recent Stories

More News
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

Based on preliminary, unaudited results, Verastem expects AVMAPKIâ„¢ FAKZYNJAâ„¢ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million...

VSTM : 6.65 (-0.30%)
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase...

VSTM : 6.65 (-0.30%)
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim...

VSTM : 6.65 (-0.30%)
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development ...

VSTM : 6.65 (-0.30%)
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled...

VSTM : 6.65 (-0.30%)
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its previously announced...

VSTM : 6.65 (-0.30%)
Verastem Oncology Announces Proposed Public Offering of Common Stock

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell shares...

VSTM : 6.65 (-0.30%)
Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled...

VSTM : 6.65 (-0.30%)
Verastem: Q3 Earnings Snapshot

Verastem: Q3 Earnings Snapshot

VSTM : 6.65 (-0.30%)
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Achieved AVMAPKIâ„¢ FAKZYNJAâ„¢ CO-PACK net product revenue of $11.2 million VS-7375 cleared first two monotherapy dose levels with no dose-limiting toxicities reported;...

VSTM : 6.65 (-0.30%)

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

3rd Resistance Point 7.18
2nd Resistance Point 6.99
1st Resistance Point 6.82
Last Price 6.65
1st Support Level 6.47
2nd Support Level 6.28
3rd Support Level 6.11

See More

52-Week High 11.24
Fibonacci 61.8% 8.48
Fibonacci 50% 7.63
Fibonacci 38.2% 6.77
Last Price 6.65
52-Week Low 4.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar